Pfizer Inc. (NYSE:PFE) Shares Sold by Scott & Selber Inc.

Scott & Selber Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 4.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,191 shares of the biopharmaceutical company’s stock after selling 1,588 shares during the period. Scott & Selber Inc.’s holdings in Pfizer were worth $1,239,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in PFE. Sargent Investment Group LLC lifted its stake in Pfizer by 5.7% during the first quarter. Sargent Investment Group LLC now owns 15,396 shares of the biopharmaceutical company’s stock valued at $558,000 after buying an additional 827 shares in the last quarter. Sage Capital Advisors llc boosted its stake in Pfizer by 0.8% in the 1st quarter. Sage Capital Advisors llc now owns 38,945 shares of the biopharmaceutical company’s stock worth $1,411,000 after purchasing an additional 315 shares during the period. Semmax Financial Advisors Inc. grew its position in Pfizer by 6.7% during the 1st quarter. Semmax Financial Advisors Inc. now owns 130,378 shares of the biopharmaceutical company’s stock worth $4,724,000 after purchasing an additional 8,174 shares in the last quarter. Toews Corp ADV acquired a new stake in Pfizer during the 1st quarter valued at $946,000. Finally, Roosevelt Investment Group LLC lifted its holdings in shares of Pfizer by 11.8% in the first quarter. Roosevelt Investment Group LLC now owns 91,124 shares of the biopharmaceutical company’s stock valued at $3,301,000 after purchasing an additional 9,625 shares in the last quarter. Institutional investors own 67.36% of the company’s stock.

Shares of PFE stock opened at $40.02 on Friday. The business’s 50 day moving average is $37.93 and its two-hundred day moving average is $36.89. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 12 month low of $31.61 and a 12 month high of $43.08. The company has a market cap of $223.22 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.15. The business had revenue of $14.58 billion for the quarter, compared to analyst estimates of $13.41 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. Pfizer’s revenue was up 44.6% compared to the same quarter last year. During the same period last year, the business posted $0.80 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. Pfizer’s payout ratio is presently 52.88%.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the sale, the senior vice president now owns 13,748 shares of the company’s stock, valued at approximately $561,193.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.08% of the stock is currently owned by insiders.

Several research analysts recently weighed in on PFE shares. DZ Bank reissued a “buy” rating and set a $41.00 price target on shares of Pfizer in a research report on Wednesday, February 3rd. TheStreet raised shares of Pfizer from a “c+” rating to a “b-” rating in a research report on Monday, May 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.11 price objective on shares of Pfizer in a research report on Thursday. SVB Leerink increased their target price on shares of Pfizer from $39.00 to $43.00 and gave the stock a “market perform” rating in a research report on Tuesday. Finally, Barclays boosted their price target on shares of Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 5th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $39.74.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: What is a stock split?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.